![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Under the agreement, the companies will jointly develop intravenous NRX-100 (ketamine hydrochloride) and is being developed to treat suicidal depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: NRX-100
Highest Development Status: Phase III Product Type: Small molecule
Recipient: NRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2023